N-cadherin as a therapeutic target in cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
During tumor progression, cancer cells undergo dramatic changes in the expression profile of adhesion molecules resulting in detachment from original tissue and acquisition of a highly motile and invasive phenotype. A hallmark of this change, also referred to as the epithelial-mesenchymal transition, is the loss of E- (epithelial) cadherin and the de novo expression of N- (neural) cadherin adhesion molecules. N-cadherin promotes tumor cell survival, migration and invasion, and a high level of its expression is often associated with poor prognosis. N-cadherin is also expressed in endothelial cells and plays an essential role in the maturation and stabilization of normal vessels and tumor-associated angiogenic vessels. Increasing experimental evidence suggests that N-cadherin is a potential therapeutic target in cancer. A peptidic N-cadherin antagonist (ADH-1) has been developed and has entered clinical testing. In this review, the authors discuss the biochemical and functional features of N-cadherin, its potential role in cancer and angiogenesis, and summarize the preclinical and clinical results achieved with ADH-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of N‐cadherin in bone formation
Marie, P. J. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10073 · Cited by 132 · cited 2×
“Drugs (2007) 16(4) 453 reduces the expression of bone matrix proteins and of the genes that are necessary for osteoblast differentiation, resulting in N-cadherin proteolytic cleavage and osteoblast apoptosis [23].”
Background
Cited by
Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y., & Johnson, K. R. (2008) · Journal of Cell Science · doi:10.1242/jcs.000455 · Cited by 767
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Involvement of Members of the Cadherin Superfamily in Cancer
Berx, G., & van Roy, F. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003129 · Cited by 709
Gravdal, K., Halvorsen, O. J., Haukaas, S. A., & Akslen, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1263 · Cited by 562
EndMT contributes to the onset and progression of cerebral cavernous malformations
Maddaluno, L., Rudini, N., Cuttano, R., Bravi, L., Giampietro, C., Corada, M., Ferrarini, L., Orsenigo, F., Papa, E., Boulday, G., et al. (2013) · Nature · doi:10.1038/nature12207 · Cited by 486
Metadata
- Authors
- Mariotti, A., Perotti, A., Sessa, C., & Rüegg, C.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2007-03-20
- Volume
- 16
- Issue
- 4
- Pages
- 451-465
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2111124508
- Cited by
- 122
- References
- 1
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N-cadherin as a therapeutic target in cancer. https://app.cochat.ai/papers/10.1517/13543784.16.4.451
- The paper
- Mariotti, A., Perotti, A., Sessa, C., & Rüegg, C. (2007). N-cadherin as a therapeutic target in cancer. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.16.4.451
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.